

119TH CONGRESS
1ST SESSION

H. R. 2107

To amend title III of the Public Health Service Act to reauthorize the program of payments to children’s hospitals that operate graduate medical education programs, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 14, 2025

Mr. CRENSHAW (for himself, Mrs. MILLER of Illinois, Mrs. MILLER-MEEKS, Mr. PFLUGER, Mr. ELLZEY, Mr. VAN DREW, Mr. GREEN of Tennessee, Mr. ROUZER, Mrs. HARSHBARGER, Mr. GROTHMAN, Mr. JACKSON of Texas, and Mr. SCOTT FRANKLIN of Florida) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend title III of the Public Health Service Act to reauthorize the program of payments to children’s hospitals that operate graduate medical education programs, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Children’s Hospital
5 GME Support Reauthorization Act of 2025”.

1 **SEC. 2. PROGRAM OF PAYMENTS TO CHILDREN'S HOS-**
2 **PITALS THAT OPERATE GRADUATE MEDICAL**
3 **EDUCATION PROGRAMS.**

4 Section 340E of the Public Health Service Act (42
5 U.S.C. 256e) is amended—

6 (1) in subsection (a), by striking “2023” and
7 inserting “2030”;

8 (2) in subsection (b)(3)(D), by inserting “and
9 the end of fiscal year 2030,” after “fiscal year
10 2022,”;

11 (3) in subsection (e), by adding at the end the
12 following new paragraph:

13 “(4) PROHIBITION ON PAYMENTS TO HOS-
14 PITALS FURNISHING SPECIFIED PROCEDURES AND
15 DRUGS TO MINORS.—

16 “(A) IN GENERAL.—Notwithstanding any
17 other provision of this section, no payment may
18 be made under this section to a children’s hos-
19 pital for a fiscal year (beginning with fiscal year
20 2026) if, at any point during the preceding fis-
21 cal year, such hospital furnished specified pro-
22 cedures and drugs (as defined in subsection (g))
23 to an individual under 18 years of age.

24 “(B) SPECIAL RULE FOR FISCAL YEAR
25 2026.—In applying subparagraph (A) with re-

1 spect to payments described in such subpara-
2 graph for fiscal year 2026—

3 “(i) the reference to ‘for a fiscal year’
4 shall be treated as a reference to ‘for any
5 portion of fiscal year 2026 occurring after
6 December 31, 2025’; and

7 “(ii) the reference to ‘the preceding
8 fiscal year’ shall be treated as a reference
9 to ‘the period beginning on September 1,
10 2025, and ending on December 31, 2025’.

11 “(C) RULE OF CONSTRUCTION.—Nothing
12 in this paragraph shall be construed as prohib-
13 iting payments for a fiscal year (or, in the case
14 of payments for fiscal year 2026, during the
15 portion of such fiscal year described in subpara-
16 graph (B)(i)) to a hospital that, during the pre-
17 ceding fiscal year (or, in the case of payments
18 for fiscal year 2026, during the period de-
19 scribed in subparagraph (B)(ii)), furnished
20 mental or behavioral health services to individ-
21 uals under 18 years of age for the treatment of
22 gender dysphoria not consisting of specified
23 procedures and drugs.”;

24 (4) in subsection (f)—

25 (A) in paragraph (1)(A)—

1 (i) in clause (v), by striking “and” at
2 the end;

3 (ii) in clause (vi), by striking the pe-
4 riod at the end and inserting “; and”; and

5 (iii) by adding at the end the fol-
6 lowing:

7 “(vii) for each of fiscal years 2026
8 through 2030, \$124,000,000.”; and

9 (B) in paragraph (2)—

10 (i) in subparagraph (E), by striking
11 “and” at the end;

12 (ii) in subparagraph (F), by striking
13 the period at the end and inserting “;
14 and”; and

15 (iii) by adding at the end the fol-
16 lowing:

17 “(G) for each of fiscal years 2026 through
18 2030, \$261,000,000”; and

19 (5) in subsection (g), by adding at the end the
20 following new paragraph:

21 “(4) SPECIFIED PROCEDURES AND DRUGS.—

22 “(A) IN GENERAL.—Except as provided in
23 subparagraph (B), the term ‘specified proce-
24 dures and drugs’ means, with respect to an in-
25 dividual, any of the following:

“(i) Performing any surgery for the purpose of changing the body of such individual to no longer correspond to the individual’s sex, including—

“(I) castration;

“(II) orchiectomy;

“(III) scrotoplasty;

“(IV) vasectomy;

“(V) hysterectomy;

“(VI) oophorectomy;

“(VII) ovariectomy;

“(VIII) metoidioplasty;

“(IX) penectomy;

“(X) phalloplasty;

“(XI) vaginoplasty;

“(XII) vaginectomy;

“(XIII) vulvoplasty;

“(XIV) reduction

thyrochondroplasty;

“(XV) chondrolaryngoplasty, or

any plastic surgery that feminizes or

masculinizes the facial features;

“(XVI) mastectomy, or any

placement of chest implants to create

feminine breasts; and

1 “(XVII) Any placement of fat or
2 artificial implants in the gluteal re-
3 gion.

4 “(ii) Administering, supplying, pre-
5 scribing, dispensing, distributing, or other-
6 wise conveying to an individual medications
7 for the purposes described in clause (i), in-
8 cluding gonadotrophin releasing hormone
9 (GnRH) analogues or other puberty-block-
10 ing drugs to stop or delay normal puberty,
11 and estrogen, testosterone, progesterone,
12 or other androgens to an individual in an
13 amount greater than would normally be
14 produced endogenously in a healthy indi-
15 vidual of that individual’s age and sex.

16 “(B) EXCEPTION.—Subparagraph (A)
17 shall not apply to the provision by a physician
18 or health care provider, with the consent of the
19 child’s parent or legal guardian, of—

20 “(i) puberty suppression or blocking
21 prescription drugs for the purpose of nor-
22 malizing puberty for a minor experiencing
23 precocious puberty;

1 “(ii) appropriate and medically nec-
2 essary procedures or treatments to correct
3 for—

4 “(I) a medically verifiable genetic
5 disorder of sex development, includ-
6 ing—

7 “(aa) 46,XX chromosomes
8 with virilization;

9 “(bb) 46,XY chromosomes
10 with undervirilization; and

11 “(cc) both ovarian and tes-
12 ticular tissue; or

13 “(II) sex chromosome structure,
14 sex steroid hormone production, or
15 sex hormone action, if determined to
16 be abnormal by a physician through
17 genetic or biochemical testing;

18 “(iii) infection, disease, injury, or dis-
19 order caused or exacerbated by previous
20 medical procedures as defined in sub-
21 section (g)(4)(A); or

22 “(iv) a physical disorder, physical in-
23 jury, or physical illness that would, as cer-
24 tified by a physician, place the individual
25 in imminent danger of death or impair-

1 ment of a major bodily function unless the
2 procedure is performed, not including if
3 the procedure or drug is for the purpose
4 described in subsection (g)(4)(A)(i).

5 “(C) SEX.—For purposes of subparagraph
6 (A), the term ‘sex’ means the indication of male
7 or female sex by reproductive potential or ca-
8 pacity, sex chromosomes, naturally occurring
9 sex hormones, gonads, or internal or external
10 genitalia present at birth.”.

○